Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Avidity Biosciences Analyst Ratings and Price Targets | NASDAQ:RNA | Benzinga
Avidity Biosciences Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Avidity Biosciences Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wolfe Research
Raymond James
Citigroup
Barclays
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Avidity Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/17/2025 | Buy Now | — | Wolfe Research | Andy Chen46% | → $55 | Initiates | → Outperform | Get Alert |
| 06/11/2025 | Buy Now | — | Raymond James | Michael Freeman27% | → $65 | Initiates | → Strong Buy | Get Alert |
| 06/10/2025 | Buy Now | — | Citigroup | Geoff Meacham62% | $70 → $75 | Maintains | Buy | Get Alert |
| 06/10/2025 | Buy Now | — | Barclays | Gena Wang52% | $57 → $59 | Maintains | Overweight | Get Alert |
| 06/09/2025 | Buy Now | — | B of A Securities | Geoff Meacham62% | $48 → $54 | Maintains | Buy | Get Alert |
| 06/09/2025 | Buy Now | — | Chardan Capital | Keay Nakae56% | $65 → $75 | Maintains | Buy | Get Alert |
| 05/12/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein61% | $72 → $68 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | — | Chardan Capital | Keay Nakae56% | $65 → $65 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | — | Chardan Capital | Keay Nakae56% | $65 → $65 | Maintains | Buy | Get Alert |
| 04/09/2025 | Buy Now | — | Needham | Joseph Stringer61% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein61% | $72 → $72 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | — | Needham | Joseph Stringer61% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein61% | $72 → $72 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | — | Chardan Capital | Keay Nakae56% | $65 → $65 | Maintains | Buy | Get Alert |
| 03/13/2025 | Buy Now | — | Citigroup | Geoff Meacham62% | → $70 | Initiates | → Buy | Get Alert |
| 03/12/2025 | Buy Now | — | BMO Capital | Kostas Biliouris34% | → $72 | Initiates | → Outperform | Get Alert |
| 03/10/2025 | Buy Now | — | B of A Securities | Geoff Meacham62% | $51 → $48 | Maintains | Buy | Get Alert |
| 03/07/2025 | Buy Now | — | Scotiabank | Louise Chen57% | → $70 | Initiates | → Sector Outperform | Get Alert |
| 02/28/2025 | Buy Now | — | Barclays | Gena Wang52% | $63 → $57 | Maintains | Overweight | Get Alert |
| 02/28/2025 | Buy Now | — | Chardan Capital | Keay Nakae56% | $65 → $65 | Maintains | Buy | Get Alert |
| 01/21/2025 | Buy Now | — | RBC Capital | Luca Issi45% | $67 → $67 | Reiterates | Outperform → Outperform | Get Alert |
| 01/10/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein61% | $72 → $72 | Reiterates | Buy → Buy | Get Alert |
| 12/20/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein61% | → $72 | Initiates | → Buy | Get Alert |
| 11/26/2024 | Buy Now | — | RBC Capital | Luca Issi45% | → $67 | Initiates | → Outperform | Get Alert |
| 11/13/2024 | Buy Now | — | Chardan Capital | Keay Nakae56% | $65 → $65 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | — | Needham | Joseph Stringer61% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | — | Needham | Joseph Stringer61% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2024 | Buy Now | — | Chardan Capital | Keay Nakae56% | $60 → $65 | Maintains | Buy | Get Alert |
| 10/21/2024 | Buy Now | — | TD Cowen | Ritu Baral40% | $56 → $78 | Maintains | Buy | Get Alert |
| 09/24/2024 | Buy Now | — | Goldman Sachs | Corinne Johnson23% | → $59 | Initiates | → Buy | Get Alert |
| 09/18/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt33% | $96 → $96 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt33% | $96 → $96 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt33% | $96 → $96 | Reiterates | Overweight → Overweight | Get Alert |
| 08/28/2024 | Buy Now | — | Barclays | Gena Wang52% | → $63 | Initiates | → Overweight | Get Alert |
| 08/26/2024 | Buy Now | — | Evercore ISI Group | Josh Schimmer55% | $54 → $53 | Maintains | Outperform | Get Alert |
| 08/13/2024 | Buy Now | — | Needham | Joseph Stringer61% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | — | Evercore ISI Group | Josh Schimmer55% | $45 → $54 | Maintains | Outperform | Get Alert |
| 08/09/2024 | Buy Now | — | Chardan Capital | Keay Nakae56% | $45 → $60 | Maintains | Buy | Get Alert |
| 06/13/2024 | Buy Now | — | B of A Securities | Geoff Meacham62% | $40 → $45 | Maintains | Buy | Get Alert |
| 06/12/2024 | Buy Now | — | Needham | Joseph Stringer61% | $35 → $46 | Maintains | Buy | Get Alert |
| 06/12/2024 | Buy Now | — | Chardan Capital | Keay Nakae56% | $33 → $45 | Maintains | Buy | Get Alert |
| 06/12/2024 | Buy Now | — | Evercore ISI Group | Josh Schimmer55% | $40 → $45 | Maintains | Outperform | Get Alert |
| 06/10/2024 | Buy Now | — | Needham | Joseph Stringer61% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | — | Needham | Joseph Stringer61% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | — | Chardan Capital | Keay Nakae56% | $33 → $33 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | — | B of A Securities | Geoff Meacham62% | → $40 | Initiates | → Buy | Get Alert |
| 04/11/2024 | Buy Now | — | Needham | Joseph Stringer61% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt33% | → $60 | Initiates | → Overweight | Get Alert |
| 03/05/2024 | Buy Now | — | Chardan Capital | Keay Nakae56% | $23 → $33 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | — | Needham | Joseph Stringer61% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | — | Needham | Joseph Stringer61% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | — | Chardan Capital | Keay Nakae56% | → $23 | Reiterates | Buy → Buy | Get Alert |
| 01/03/2024 | Buy Now | — | Wells Fargo | Yanan Zhu44% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/29/2023 | Buy Now | — | Needham | Joseph Stringer61% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | — | Credit Suisse | Judah Frommer65% | → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | Buy Now | — | Chardan Capital | Keay Nakae56% | $27 → $23 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | — | Needham | Joseph Stringer61% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | Buy Now | — | Evercore ISI Group | Josh Schimmer55% | → $20 | Upgrade | In-Line → Outperform | Get Alert |
| 05/17/2023 | Buy Now | — | Needham | Joseph Stringer61% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | — | Wells Fargo | Yanan Zhu44% | $55 → $50 | Maintains | Overweight | Get Alert |
| 05/10/2023 | Buy Now | — | Credit Suisse | Judah Frommer65% | → $30 | Reiterates | → Outperform | Get Alert |
| 04/28/2023 | Buy Now | — | Needham | Joseph Stringer61% | → $35 | Reiterates | → Buy | Get Alert |
| 03/31/2023 | Buy Now | — | Credit Suisse | Judah Frommer65% | $35 → $30 | Maintains | Outperform | Get Alert |
| 03/31/2023 | Buy Now | — | Evercore ISI Group | Joshua Schimmer45% | → $20 | Downgrade | Outperform → In-Line | Get Alert |
| 03/31/2023 | Buy Now | — | Chardan Capital | Keay Nakae56% | → $27 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | — | Credit Suisse | Judah Frommer65% | → $35 | Reiterates | → Outperform | Get Alert |
| 03/01/2023 | Buy Now | — | Chardan Capital | Keay Nakae56% | → $27 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | — | Needham | Joseph Stringer61% | → $35 | Reiterates | → Buy | Get Alert |
| 01/04/2023 | Buy Now | — | Wells Fargo | Yanan Zhu44% | $60 → $55 | Maintains | Overweight | Get Alert |
| 12/15/2022 | Buy Now | — | Credit Suisse | Judah Frommer65% | $33 → $35 | Maintains | Outperform | Get Alert |
| 12/15/2022 | Buy Now | — | Raymond James | Steven Seedhouse57% | $30 → $71 | Maintains | Strong Buy | Get Alert |
| 12/14/2022 | Buy Now | — | Raymond James | Steven Seedhouse57% | $30 → $71 | Maintains | Strong Buy | Get Alert |
| 11/09/2022 | Buy Now | — | Credit Suisse | Judah Frommer65% | $32 → $33 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | — | Raymond James | Steven Seedhouse57% | $29 → $30 | Maintains | Strong Buy | Get Alert |
| 09/27/2022 | Buy Now | — | Needham | Joseph Stringer61% | $50 → $35 | Maintains | Buy | Get Alert |
| 09/27/2022 | Buy Now | — | Chardan Capital | Keay Nakae56% | $29 → $27 | Maintains | Buy | Get Alert |
| 07/20/2022 | Buy Now | — | Chardan Capital | Keay Nakae56% | → $29 | Initiates | → Buy | Get Alert |
| 07/12/2022 | Buy Now | — | Raymond James | Steven Seedhouse57% | → $29 | Initiates | → Strong Buy | Get Alert |
FAQ
What is the target price for Avidity Biosciences (RNA) stock?
The latest price target for Avidity Biosciences (NASDAQ:RNA) was reported by Wolfe Research on June 17, 2025. The analyst firm set a price target for $55.00 expecting RNA to rise to within 12 months (a possible 86.95% upside). 38 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avidity Biosciences (RNA)?
The latest analyst rating for Avidity Biosciences (NASDAQ:RNA) was provided by Wolfe Research, and Avidity Biosciences initiated their outperform rating.
When was the last upgrade for Avidity Biosciences (RNA)?
The last upgrade for Avidity Biosciences Inc happened on May 22, 2023 when Evercore ISI Group raised their price target to $20. Evercore ISI Group previously had an in-line for Avidity Biosciences Inc.
When was the last downgrade for Avidity Biosciences (RNA)?
The last downgrade for Avidity Biosciences Inc happened on March 31, 2023 when Evercore ISI Group changed their price target from N/A to $20 for Avidity Biosciences Inc.
When is the next analyst rating going to be posted or updated for Avidity Biosciences (RNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avidity Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avidity Biosciences was filed on June 17, 2025 so you should expect the next rating to be made available sometime around June 17, 2026.
Is the Analyst Rating Avidity Biosciences (RNA) correct?
While ratings are subjective and will change, the latest Avidity Biosciences (RNA) rating was a initiated with a price target of $0.00 to $55.00. The current price Avidity Biosciences (RNA) is trading at is $29.42, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
